Cyrus Biotechnology

Seattle, United States Founded: 2014 • Age: 12 yrs
Cloud-based protein-modeling software is developed for drug discovery.

About Cyrus Biotechnology

Cyrus Biotechnology is a Healthcare company based in Seattle (United States) founded in 2014. Cloud-based protein-modeling software is developed for drug discovery. Cyrus Biotechnology has raised $31.99 million across 11 funding rounds from investors including HHS, Orbimed and Trinity Ventures. The company has 23 employees. Cyrus Biotechnology has completed 1 acquisition, including Orthogonal Biologics. Cyrus Biotechnology offers products and services including IdeS, IL-22 Variant, and sACE2.v2-Fc. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is CYRUS BIOTECHNOLOGY INC. Its competitors include Vividion Therapeutics, Seer and ProteinSimple; 3 of its 3 listed competitors have raised funding.

Company details

Cyrus Biotechnology was founded in 2014 in Seattle, United States, within the biotechnology sector. Cloud-based software for protein modeling in drug discovery is provided. The primary product, Cyrus Bench, is offered as a modified version of the open-source Rosetta molecular modeling tool. This is bundled with essential bio-molecular computation resources, including BLAST, and features a custom user interface to support full utilization.

  • Headquarters Seattle, United States
  • Employees 23
  • Sectors
    Healthcare
  • Website cyrusbio.com
  • Social LinkedIn X
  • Legal Name Cyrus Biotechnology Inc.
Key Metrics
  • Total Equity Funding
    $31.99M (USD)

    in 11 rounds

  • Latest Funding Round
    $300K (USD), Grant

    Dec 2024

  • Investors
    HHS

    & 10 more

  • Employee Count
    23
  • Investments & Acquisitions

Products & Services of Cyrus Biotechnology

Cyrus Biotechnology offers a comprehensive portfolio of products and services, including IdeS, IL-22 Variant, and sACE2.v2-Fc.

IdeS
Therapeutic

Protein for IgG depletion in autoimmune diseases.

IL-22 Variant
Therapeutic

Fusion protein for gastrointestinal and metabolic conditions.

sACE2.v2-Fc
Therapeutic

Candidate for COVID-19 prophylaxis in immunocompromised individuals.

Funding Insights of Cyrus Biotechnology

Cyrus Biotechnology has successfully raised a total of $31.99M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $300 thousand completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $31.99M
  • Total Rounds 11
  • Last Round Grant β€” $300,000
  • First Round $850,000

    (May 2015)

  • Investors Count 11

Latest 10 of 11 funding rounds of Cyrus Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2024$300,000Grant––
Sep 2024$298,915Grant––
Feb 2024$2.69MSeries B––
–
Dec 2021$18.35MSeries B–Orbimed, Trinity Ventures
–
Apr 2021$256,565Grant––
Jul 2017$8.02MSeries A–Trinity Ventures
Feb 2017$1.04MSeed––
–
Nov 2016$490,000Seed––
–
Apr 2016$535,000Seed––
–
Mar 2016$224,908Grant––
Valuation history

11 investors in total: 11 institutional.

Investors in Cyrus Biotechnology

Cyrus Biotechnology has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Orbimed and Trinity Ventures.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Venture capital firm investing in early-stage technology and real estate companies.
trinityventures.com
Agent Capital is focused on healthcare venture capital investments.
agentcapital.comWaltham, United States
Venture capital investing and portfolio management services for accredited investors.
av.vc
Early-stage venture capital is provided to US companies across sectors.
wrfseattle.orgSeattle, United States
Early-stage investments are targeted by iSelect Fund in key sectors.
iselectfund.comSt. Louis, United States
wrule.vc
Tech & Life-Sciences focused Stage-agnostic VC firm investing in geographies such as North America
springrockventures.comSeattle, United States
thewfund.com
Digital content on health and lifestyle topics is offered.
medtechwings.com
Premium access

Investor details for Cyrus Biotechnology

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Cyrus Biotechnology

21 people are tracked at Cyrus Biotechnology (5 in leadership, 5 in board & advisors, 11 in team); the tracked headcount is 23.

NameRoleGroup
Lucas Nivon
CEOLeadership
Eric Tarcha
VP of Drug DiscoveryLeadership
Mark Benjamin
President & EVP Business DevelopmentLeadership
Erik Procko
Director of DiscoveryLeadership
Yifan Song
Chief Technology OfficerLeadership
David Baker
Scientific Co-Founder & AdvisorBoard & advisors
Eric Bell
Board MemberBoard & advisors
Chad Waite
Board MemberBoard & advisors
Will Chen
Scientific AdvisorBoard & advisors
Jeff Gray
Scientific AdvisorBoard & advisors
Andy Jerome
Program & Business Development ManagerTeam
Brandon Frenz
Scientific Software DeveloperTeam
Max Sauer
Scientist IIITeam
David Thieker
Protein Engineer ScientistTeam
Benjamin Dutzar
Scientist IITeam
Ragul Gowthaman
Protein Engineer ScientistTeam
Emily Frazier
Scientist IITeam
Galina Stepanyuk
Scientist IVTeam
Kui Chan
Scientist IVTeam
Steven Lewis
ScientistTeam

1 more people are available in the full profile.

Premium access

Complete people profiles for Cyrus Biotechnology

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Cyrus Biotechnology

Cyrus Biotechnology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Orthogonal Biologics.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Protein drug manufacturing and research services are provided.
orthogonalbiologics.comUnited States2020Dec 2021β€’β€’β€’β€’
Premium access

Complete acquisition details for Cyrus Biotechnology

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Cyrus Biotechnology

4 dated milestones of Cyrus Biotechnology across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded Cyrus Biotechnology is founded.
  2. Funding First funding round of $850K.
  3. Acquisition Acquires Orthogonal Biologics.
  4. Funding Latest funding round, Grant, of $300K.

Competitors of Cyrus Biotechnology

Cyrus Biotechnology has 3 listed competitors in our database, 3 of them funded. They include Vividion Therapeutics, Seer and ProteinSimple.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
vividion.com2016Oceanside, United States$270.5M123
Developing novel drugs based on a proteome-wide ligand and target discovery platform
seer.bio2017San Francisco, United States$127.5M89
Proteomics platform developed for early cancer and neurological disease detection.
proteinsimple.com2004San Jose, United States$114.29M157
Provider tools to help researchers with protein analysis
Premium access

Detailed competitors of Cyrus Biotechnology

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Cyrus Biotechnology

The website of Cyrus Biotechnology (cyrusbio.com) receives about 1.9K visits a month.

  • Monthly visits
    1.9K

    ▲ 105.1% vs previous month

Similar websites

Websites whose visitors overlap most with Cyrus Biotechnology. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
curibio.com
100%
7K#3,017,939View details
parsebiosciences.com
97%
62.7K#493,988View details
evotec.com
81%
91K#396,653View details
talus.bio
30%
4.4K#4,306,649View details
alpenglowbiosciences.com
30%
3.7K#4,504,338View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 17 similar websites and full traffic analytics for Cyrus Biotechnology

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 17 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Life Sciences Platforms & Tools

3 companies that operate in the same segment as Cyrus Biotechnology (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Medidata is recognized as a leading provider of SaaS solutions for clinical research.
1999New York, New York, United StatesUSD 41.5 M
AI-based solutions for health management are provided.
2015Dallas, Texas, United StatesUSD 2.8 B1,111
Real-world health data is provided for research and decisions.
2012Menlo Park, California, United StatesUSD 259.16 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cyrus Biotechnology

Premium access

Complete news archive for Cyrus Biotechnology

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cyrus Biotechnology

Cyrus Biotechnology was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Cyrus Biotechnology is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.

Cyrus Biotechnology is a funded company, having raised a total of $31.99M across 11 funding rounds to date. The company's 1st funding round was a Grant of $224.91K, raised on May 2015.

Cyrus Biotechnology has 23 employees.

Cyrus Biotechnology was founded in 2014 in Seattle, United States, within the biotechnology sector. Cloud-based software for protein modeling in drug discovery is provided. The primary product, Cyrus Bench, is offered as a modified version of the open-source Rosetta molecular modeling tool. This is bundled with essential bio-molecular computation resources, including BLAST, and features a custom user interface to support full utilization.

Cyrus Biotechnology's top competitors include Vividion Therapeutics, ProteinSimple and Seer.

Cyrus Biotechnology offers IdeS, IL-22 Variant, and sACE2.v2-Fc.

Cyrus Biotechnology has made 1 acquisition, including Orthogonal Biologics.

Cyrus Biotechnology has 11 investors. Key investors include HHS, Orbimed, Trinity Ventures, Agent Capital, and Alumni Ventures.

Cyrus Biotechnology operates through Cyrus Biotechnology Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available